GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
Modern lifestyle diseases remain a persistent challenge in healthcare. Currently, about 422 million people worldwide are affected by diabetes, while 1 in 8 people are living with obesity. The development of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has marked a significant milestone in tr...
Saved in:
Main Authors: | Patrycja Kupnicka (Author), Małgorzata Król (Author), Justyna Żychowska (Author), Ryszard Łagowski (Author), Eryk Prajwos (Author), Anna Surówka (Author), Dariusz Chlubek (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023) -
Retatrutide - revolutionary recently developed GLP agonist - literature review
by: Patrycja Brzozowska, et al.
Published: (2024) -
The Impact of GLP-1 Agonists on Depression Treatment: A Literature Review
by: Paulina Lemieszek, et al.
Published: (2024) -
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024) -
Danuglipron - an innovate GLP agonist - literature short review
by: Agata Frańczuk, et al.
Published: (2024)